

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-18. (Canceled)

19. (Previously Presented) An immunogenic composition according to claim 61, wherein the immunostimulant is an adjuvant.

20.-60. (Canceled)

61. (Currently Amended) An immunogenic composition comprising an immunostimulant which induces a predominantly Th1-type immune response and a polypeptide, wherein the polypeptide comprises SEQ ID NO: 113 or a fragment of SEQ ID NO: 113 comprising consisting of at least amino acid residues 367-375 of SEQ ID NO: 113, and wherein the polypeptide stimulates a human cytotoxic T lymphocyte response specific for SEQ ID NO: 113.

62. (Canceled)

63. (Previously Presented) An immunogenic composition according to claim 61, wherein the immunostimulant is selected from the group consisting of: monophosphoryl lipid A; 3-de-O-acylated monophosphoryl lipid A; and saponins.

64.-65. (Canceled)